Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Jul 2023
On Tuesday, US health regulators decided against approving a higher dosage of Regeneron's drug Eylea for the treatment of a condition that is the primary cause of blindness in the elderly.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Examines Office-Based Transperineal Prostate Biopsies Methodology.
2.
A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.
3.
Is a $2,000 Whole-Body MRI Worth It?
4.
Surgery may not be necessary to treat invasive breast cancer
5.
Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.
1.
Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options
2.
Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective
3.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
4.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
5.
Understanding Lymphedema: Symptoms, Causes, and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge